• Merck Immunotherapy Drug Shines In Lung Cancer Study

    5 monthes ago - By NPR

    Research finds that more than two-thirds of lung cancer patients who received Keytruda plus chemotherapy would be alive a year later, compared with about half of people who only got chemotherapy.
    Read more ...

     

  • Merck Tightens Its Grip on Lung Cancer, as Bristol Lags: Gadfly

    Merck Tightens Its Grip on Lung Cancer, as Bristol Lags: Gadfly

    5 monthes ago - By Washington Post


    Read more ...

     

  • Brainstorm Health: Merck's Lung Cancer Triumph, COPD and Women, Trump on Drug Prices

    5 monthes ago - By Fortune

    And happy Monday, readers! This is Sy.
    New study results released Monday continue to cement drug giant Merck's status as the force to be reckoned with in the lung cancer treatment space. Merck's flagship cancer immunotherapy Keytruda , combined with chemotherapy, helped lung cancer patients live significantly longer lives than those treated with chemotherapy alone.
    It's the latest in a string of powerful, positive clinical trial results for Keytruda, which is already approved by the Food and Drug Administration to treat multiple cancer types including melanoma and lung cancer. In fact...
    Read more ...